Medicine guide

Lyvdelzi (previously Seladelpar Gilead)

·

  • Prescription status not stated
  • Digestion, stomach, diabetes and nutrition
Made by
Gilead Sciences Ireland Unlimited Company

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

What it is for

  • Lyvdelzi is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA.

From the official label · 2026-09-30 · European Medicines Agency

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

United StatesNo exact match for this strength and form

SpainNo exact match for this strength and form

CanadaNo exact match for this strength and form

NetherlandsNo exact match for this strength and form

SwitzerlandNo exact match for this strength and form

Details

Made byGilead Sciences Ireland Unlimited Company
Active substanceSeladelpar lysine dihydrate
Used inDigestion, stomach, diabetes and nutrition
ClassificationA05AX07 · Digestion, stomach, diabetes and nutrition
Orphan medicineYes — designated for a rare disease, according to the register
Additional monitoring ▼Yes — under additional monitoring (black triangle). Report suspected side effects.
Last updated by the regulator2026-02-20
EMA product numberEMEA/H/C/004692

Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician

Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).